Ashland Inc. · NYSE:ASH

Ashland — Ashland Global Holdings — Q2 2018 Earnings Presentation

24 slides from Ashland's earnings presentation, May 1, 2018

  1. Slide 1: Second-Quarter Fiscal 2018 Earnings

    Second-Quarter Fiscal 2018 Earnings May 1, 2018 / efficacy usability allure integrity profitability

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words

  3. Slide 3: Second Quarter Summary

    Second Quarter Summary af Ashland always solving

  4. Slide 4: Ashland Global Holdings Adjusted Results Summary

    Ashland Global Holdings Inc. Adjusted Results Summary1 ($ in millions) Fiscal Second Quarter Highlights Preliminary Three months ended Mar. 31, • Sales up 21% including 9 ppts from 2018 2017 Change acquisitions/divestitures and 5 ppts from Sales $ 974 $ 806 21 % currency Gross profit $ 275 $ 228 21

  5. Slide 5: Specialty Ingredients Adjusted Results Summary

    Specialty Ingredients Adjusted Results Summary1 ($ in millions) Fiscal Second Quarter Highlights Preliminary Three months ended Mar. 31, • Sales up 19% including 10 ppts from acquisitions/divestitures and 4 ppts 2018 2017 Change from currency Sales $ 646 $ 544 19 % • EBITDA increased to $153 million

  6. Slide 6: Specialty Ingredients Sales Trends by End Market

    Specialty Ingredients Sales Trends by End Market Fiscal Second Quarter End Market Commentary ($ in millions) Three months ended Mar. 31, YTD • Robust growth across all end markets Preliminary 2018 2017 Change Change • Continued strong growth in Personal Care Personal care $ 159 $ 149 7 % 6 % biofunc

  7. Slide 7: Composites Adjusted Results Summary

    Composites Adjusted Results Summary1 ($ in millions) Fiscal Second Quarter Highlights Preliminary Three months ended Mar. 31, • Sales up 28% including 11 ppts from acquisitions and 5 ppts from 2018 2017 Change currency Sales $ 238 $ 186 28 % • EBITDA up 39% to $25 million Gross profit $ 45 $ 34 32 %

  8. Slide 8: Intermediates & Solvents Adjusted Results Summary

    Intermediates & Solvents Adjusted Results Summary1 ($ in millions) Fiscal Second Quarter Highlights Preliminary Three months ended Mar. 31, • Sales up 18% 2018 2017 Change • EBITDA increased to $12 million • EBITDA margin increased to 13.3% Sales $ 90 $ 76 18 % Gross profit $ 12 $ 5 140 % Key Driver

  9. Slide 9: Outlook Summary

    Outlook Summary af Ashland’ always solving

  10. Slide 10: New Cost Out & Organizational Effectiveness Initiative

    Ashland Global Holdings Inc. New Cost Out & Organizational Effectiveness Initiative PLAN • Leverage expected divestiture of Composites and Marl BDO facility as a catalyst to create a leaner, more competitive organization with: − Improved cost structure, streamlined decision making and more customer-

  11. Slide 11: Fiscal Year 2018 Outlook

    Ashland Global Holdings Inc. Fiscal Year 2018 Outlook Highlights Prior Outlook Updated Outlook • Increasing adjusted EPS to $3.30 - Adjusted EBITDA $3.50 reflecting improved segment - Specialty Ingredients $560 - $590 million $565 - $585 million outlooks and a lower effective tax - Composites $85 -

  12. Slide 12: Third-Quarter Fiscal 2018 Outlook

    Ashland Global Holdings Inc. Third-Quarter Fiscal 2018 Outlook Highlights • Expect Q3 adjusted EPS in the range of $0.95 - $1.05 vs. $0.83 prior year • Outlook assumes effective tax rate of 17% vs. 11% prior year Key Drivers • Strong year-over-year sales and EBITDA growth in Specialty Ingredients •

  13. Slide 13: Appendix A: Key Items and Balance Sheet

    Appendix A: Key Items and Balance Sheet

  14. Slide 14: Key Items Affecting Income

    Second Fiscal Quarter – Continuing Operations Key Items Affecting Income ($ in millions, except EPS) Operating Income Total Preliminary Unallocated After-tax Specialty and earnings 2018 Ingredients Composites I&S Other Pre-tax After-tax per Share Separation & restructuring costs $ (2) $ (10) $ (12)

  15. Slide 15: Liquidity and Net Debt

    Liquidity and Net Debt ($ in millions) Liquidity Cash $ 225 Revolver and A/R facility availability 819 Liquidity $ 1,044 Interest Debt Expiration Rate Moody's S&P 4.750% senior notes, par $1,086 08/2022 4.750% Ba3 BB- $ 1,082 Term Loan B 1 05/2024 L + 200 Ba1 BB+ 596 6.875% senior notes, par $375 05

  16. Slide 16: Appendix B: Business Profiles

    Appendix B: Business Profiles 12 Months Ended March 31, 2018

  17. Slide 17: Corporate Profile

    Corporate Profile Sales1 - $3.6 Billion By business unit By geography Specialty Europe Ingredients 35% 67% Intermediates North and Solvents 8% America2 Asia Pacific 40% 17% Latin Composites America/ 25% Other - 8% 1 For 12 months ended March 31, 2018. 2 Ashland includes only U.S. and Canada in its N

  18. Slide 18: Corporate Profile

    Corporate Profile Adjusted EBITDA1 - $637 Million Specialty NYSE Ticker Symbol: ASH Ingredients 78% Total Employees: ~6,500 Outside North America ~50% Composites 15% Number of Countries More Intermediates and in Which Ashland than 100 Solvents 7% Has Sales: 1 For 12 months ended March 31, 2018. See

  19. Slide 19: Specialty Ingredients

    Specialty Ingredients A global leader of cellulose ethers, vinyl pyrrolidones and biofunctionals Sales Sales Sales 2 by Market by Product by Geography3 PVP Pharma Coatings 17% Asia 15% 14% Europe Pacific 32% 18% Personal Cellulosics North Care 34% Other America 25% 14% 41% For 12 Months Ended March

  20. Slide 20: Composites

    Composites A global leader in unsaturated polyester resins, vinyl ester resins and gel coats Sales Sales Sales by Market by Product by Geography Marine 22% Europe 33% Construction: Residential 18% North Construction: UPR/VER2 America Latin America/ Industrial 84% 46% Other 7% 40% For 12 Months Ended

  21. Slide 21: Intermediates and Solvents

    Intermediates and Solvents A global leader in butanediol and related derivatives Sales Sales Sales by Application by Product by Geography Agriculture Asia 6% Pacific 16% Pharma Plastics/ 16% Polymers North Butanediol Derivatives America 34% 41% 59% 22% General Europe Industrial 59% 27% Electronics L

  22. Slide 22: Appendix C: Non-GAAP Reconciliation

    Appendix C: Non-GAAP Reconciliation1 1 Although Ashland provides forward-looking guidance for adjusted EBITDA, free cash flow and adjusted diluted earnings per share, Ashland is not reaffirming or providing forward-looking guidance for U.S. GAAP-reported financial measures or a reconciliation of for

  23. Slide 23: Reconciliation of Non-GAAP Data

    Ashland Global Holdings Inc. and Consolidated Subsidiaries Reconciliation of Non-GAAP Data for 12 Months Ended March 31, 2018 ($ millions, except percentages) 1 Sales Q2 18 Q1 18 Q4 17 Q3 17 Total Specialty Ingredients 646 550 598 591 2,385 Composites 238 218 219 209 884 Ashland Intermediates and So

  24. Slide 24: Trademark Notices

    ® Registered trademark, Ashland or its subsidiaries, registered in various countries ™ Trademark, Ashland or its subsidiaries, registered in various countries

Ashland Global Holdings — Q2 2018 Earnings Presentation on 6ix